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Background: Current evidence on myelopoietic growth factors is difﬁcult to overview for the practicing haematologist/
oncologist. International guidelines are sometimes conﬂicting, exclude certain patient groups, or cannot directly be
applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German
Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF,
pegylated G-CSF, and biosimilars to prevent infectious complications in cancer patients undergoing chemotherapy, in-
cluding those with haematological malignancies.
Methods: We systematically searched and evaluated current evidence. An expert panel discussed the results and
recommendations. We then compared our recommendations to current international guidelines.
Results:We summarised the data from eligible studies in evidence tables, developed recommendations for different en-
tities and risk groups.
Conclusion: Comprehensive literature search and expert panel consensus conﬁrmed many key recommendations
given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy
and pegﬁlgrastim use in haematological malignancies was rated lower compared with other guidelines.
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introduction
Myelosuppression due to cytotoxic drugs is a major limiting
factor in the treatment of malignant diseases. Neutropenia
places patients at a high risk of fever, infections, sepsis, and ul-
timately death [1, 2]. These risks are typically encountered with
a graduated approach of anti-infective prophylaxis, myelopoietic
growth factors, early empiric anti-infective treatment, and stan-
dardised diagnostic algorithms. As infection-related mortality is
typically low during short-term neutropenia, studies in the ﬁeld
use end points more easily observed but with clinical relevance,
such as febrile neutropenia (FN) or diagnosed infection. Apart
from higher hospitalisation and mortality [3–5], FN and neutro-
penia-related infections may result in dose-reduction of cyto-
toxic drugs or longer intervals between treatment courses [6].
G-CSF was licensed in 1991 by the United States Food and Drug
Administration (FDA) for use in patients undergoing cytotoxic
treatment. Like all CSFs available today, it is administered subcuta-
neously and was approved for decreasing the incidence of FN and
reducing the duration of neutropenia and fever following myeloa-
blative chemotherapy [7]. Two different G-CSF preparations are
available: non-glycosylated G-CSF ﬁlgrastim (Neupogen®; Amgen,
Thousand Oaks, CA) and glycosylated G-CSF lenograstim
(Granocyte®; Chugai, Utsunomiya, Japan). While data from two
open-label randomised studies comparing ﬁlgrastim to lenogras-
tim are conﬂicting [8, 9], and preclinical trials have demonstrated
differences between both drugs pharmacokinetics and pharmaco-
dynamics [10], and a recent systematic review demonstrated com-
parable efﬁcacy of both drug [11].
The addition of a polyethylene glycol (PEG) molecule to ﬁlgras-
tim increases the serum half-life of ﬁlgrastim and allows reducing
the frequency of G-CSF applications from a once daily to a once
per chemotherapy cycle/three weekly schedule [12]. Pegﬁlgrastim
is approved to decrease incidence of fever and infections in
patients with non-myeloid malignancies and acute leukaemia re-
ceiving chemotherapy. Pre-clinical and clinical studies suggest
that pegﬁlgrastim and ﬁlgrastim have comparable biologic activity
and safety proﬁles [13, 14] as well as clinical efﬁcacy [15–20].
More recently, biosimilar G-CSF (XM02) has been developed
[21–23] and is also named with the non-proprietary name ﬁlgras-
tim. Further biosimilars have become available on the market.
Today, the American Society of Clinical Oncology (ASCO), the
American National Comprehensive Cancer Network (NCCN),
and the European Organisation for Research and Treatment of
Cancer (EORTC) have set-up guidelines for the use of G-CSF and
GM-CSF in patients receiving chemotherapy with the objective to
prevent fever and infections and to maintain chemotherapy dose
intensity [24–27]. Following two landmark trials showing a sign-
iﬁcant reduction of FN by G-CSF administration even in inter-
mediate- and low-risk patients [28, 29], the ASCO, NCCN, and
EORTC [21, 30–32] updated their guidelines and now advocate
the use of colony-stimulating factors to prevent FN in patients at
a >20% risk for fever [30–34]. Risk factors can be used to identify
patients with a particularly high risk to develop FN in ambiguous
cases. Recently, validated risk factors for FN include prior chemo-
therapy, abnormal hepatic and renal function, low white blood
count, chemotherapy, and planned delivery of ≥85% of the dose
of chemotherapy [35]. A comparison of international guideline
recommendations is provided in Table 1.
The aim of this guideline is to identify and assess the evidence
for the effects of G-CSF, pegﬁlgrastim, and biosimilar XM02 to
assist in evidence-based clinical decisions on the primary and
secondary prevention of infections in adult patients with
haematological malignancies or solid tumours undergoing
chemotherapy.
methods
We provide a detailed description of the methodology used for
this guideline in the guideline report (supplementary File 01,
available at Annals of Oncology online). In brief, we conducted a
systematic literature search for trials using G-CSF, GM-CSF,
pegylated ﬁlgrastim, or biosimilar ﬁlgrastim as prophylaxis of FN
or infection during standard chemotherapy regimens in adult
patients with solid tumours or haematological malignancies. For
the search, we used a predeﬁned search strategy, which is also
part of the guideline report (supplementary File 01, available at
Annals of Oncology online). We conducted all literature searches
for the period January 1990 to August 2013.
Data were extracted by one reviewer and checked for accuracy
by a second. Studies were categorised into three different groups
of myelosuppression based on the risk of FN in the control arm:
low risk: 0%–20%, moderate risk: 20%–40%, and intensive ther-
apies with high risk >40% for FN. These cut-offs were chosen to
reﬂect the development and changes of the guidelines provided
by ASCO [26, 27] and NCCN [30]. Two recent guidelines used
a wider deﬁnition for ‘high-risk’ patients (>20% risk for FN)
Table 1. Comparison of international guideline recommendations
Neutropenic
event risk
ASCO 2000 [26] ASCO 2006 [27] EORTC 2010 [32] NCCN 2012 [34] AGIHO 2013
High risk Use CSF ≥ 40% Use CSF ≥20% Use CSF ≥20% Use CSF ≥20% Use CSF ≥40%
Moderate to high CSF not
recommended
Use CSF ≥20%
Intermediate Not further
speciﬁed
Recommend <20%
with risk factors
Consider CSF 10–20%
with risk factors
Consider CSF 10–20% with
risk factors
Recommend <20%
with risk factors
Low Not further
speciﬁed
Not further speciﬁed CSF is not recommended
<10%
CSF is not recommended for
most patients <10%
Not further speciﬁed
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[32, 34]; however, it was decided to stay with the pre-deﬁned
deﬁnition used in our analysis.
An expert panel of the AGIHO reviewed all evidence tables
and ranked the quality of evidence and strength of recommen-
dation separately for different groups of diseases and FN risk
categories (see guideline report for details). Levels of evidence
were ranked based on the classiﬁcation of the Infectious Disease
Society of America [36]. With this guidance, the team of
authors drafted a manuscript with evidence-based recommen-
dations and presented this document to the panel for further
discussion.
All included studies are listed in the evidence tables in supple-
mentary File 02, available at Annals of Oncology online. In these
evidence tables, studies are listed in the following order: disease
entity, CSF used, placebo-controlled study, size of study. If
sufﬁcient data were reported, studies with elderly patients are pre-
sented in separate tables. A list of chemotherapeutic regimens and
the associated risk of FN were not part of the consensus process.
Such lists are available as part of other guidelines [27, 32, 34].
Recommendations have been summarised in Tables 2 and 3.
use of G-CSF for primary prevention
of infections
solid tumours
In 12 RCTs, G-CSF was used as primary prophylaxis in patients
with solid tumours undergoing myelosuppressive chemotherapy
[21, 28, 37–43, 78–84]. One study reported only infection rates
Table 2. Use of colony stimulating factors to prevent febrile neutropenia after myelosuppressive chemotherapy
Setting Expected fever
incidence during
neutropenia
SoR QoE References Comment
G-CSF
Adult patients with solid tumours
(e.g. SCLC, sarcoma)
≥20% A I [28, 37–41]
Adult patients with breast cancer,
colorectal cancer, or ovarian cancer
<20% B I [42, 43] Since the clinical beneﬁt is relatively small, we do
not recommend routine use of G-CSF in these
circumstances.
Adult and elderly patients with HL/
NHL
≥40% A I/IIIa [44–47] QoE is I for NHL and III for HL.
Adult and elderly patients with HL/
NHL
≥20%, <40% B II/IIIa [48, 49] QoE is II for NHL and III for HL.
Adult patients with myelodysplastic
syndrome undergoing palliative
chemotherapy
≥20% D II [50, 51]
Adult patients with ALL undergoing
induction or consolidation treatment
≥40% A II [52–54]
Adult patients with ALL undergoing
maintenance treatment
Any C III No data
Adult patients with AML
undergoing induction or
consolidation chemotherapy
≥40% C I/II [55–61] Good evidence against a beneﬁt, not generally
recommended. QoE is I for induction and II for
consolidation chemotherapy.
Elderly patients with AML
undergoing induction chemotherapy
≥40% C I [62–69] Good evidence against a beneﬁt, not generally
recommended.
Other tumours and/or other risk
categories
Any B III [35] Decision for G-CSF depending on individual
patient risk factors
Pegﬁlgrastim
Adult patients with solid tumours
(e.g. breast cancer)
≥20% A I [15–17, 29,
70]
Non-inferior to G-CSF
Adult patients with malignant
lymphoma
≥20% B II [18–20] No studies testing for non-inferiority
Other tumours and/or other risk
categories
Any B III [35] Decision for pegﬁlgrastim depending on individual
patient risk factors
XM02
Adult patients with NHL, breast, or
lung cancer
≥20% A I [21–23] Non-inferior to ﬁlgrastim
aNote further comments in the text.
SoR, strength of recommendation; QoE, quality of evidence.
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but not FN and was assigned to the high-risk group based on a
54% infection rate in the control group [41].
high risk for FN: >40%. Seven studies assessed G-CSF in high-
risk patients (FN >40%) [37–41, 78, 80, 81, 83, 84]. Of these, ﬁve
trials demonstrated a statistically and clinically signiﬁcant
reduction of FN or infection in the G-CSF group compared with
the control group [37–41]. Three of these trials were placebo-
controlled [37–39], and four were conducted in patients with
SCLC [38–41], while one study assessed patients with sarcoma
[37]. In the remaining two studies, the reduction of FN or infection
in the G-CSF arm was not statistically signiﬁcant [78, 84].
moderate risk for FN: 20%–40%. Three studies assessed G-CSF
in moderate risk patients with SCLC [28], breast cancer [21], or
metastatic germ-cell tumour [79]. In the study with SCLC
patients (N = 186) [28], the risk for FN was signiﬁcantly reduced
from 32% in the control group to 18% in the G-CSF group
(P = 0.01). In the studies in patients with germ-cell tumour [79]
and breast cancer [21], the difference between treatment groups
did not reach statistical signiﬁcance.
low risk for FN: <20%. Two studies assessed G-CSF in patient
with low-risk FN [42, 43]. In one large (N = 506) study with
early-stage breast cancer patients, the risk for FN was reduced
from 6.6% in the control group to 1.2% in the G-CSF group,
P = 0.004 [43]. Another trial with ovarian cancer patients
(N = 80) did not show a clinically or statistically signiﬁcant
difference in the incidence of FN between the treatment groups
[42].
start of CSF in patients with solid tumours: In four RCTs, the
inﬂuence of CSF timing was investigated [43, 71, 85, 86]. We
excluded two of these studies published in Japanese only [85,
86]. One study compared three different schedules for
administration of G-CSF in 33 patients with non-small-cell lung
cancer [71]. No signiﬁcant differences in terms of infectious
complications were noted. One trial tested ﬁve different dosing
regimens for G-CSF in breast cancer patients [43]. The authors
reported no signiﬁcant differences between any of these
schedules. However, most landmark trials started G-CSF
administration between 1 and 6 days after chemotherapy, and
there are currently no sufﬁciently powered clinical trials to allow
deﬁnite conclusions on the optimal timing of CSFs.
Table 3. Other recommendations
Setting Recommendation SoR QoE References Comment
G-CSF
Adult patients with solid tumours Start G-CSF early after
chemotherapy
A I [28, 37–41]
Adult patients with solid tumours Start G-CSF at onset of
neutropenia
C II [71] Starting G-CSF after onset of neutropenia may be
equally effective, but is not generally
recommended due to lack of data
Adult and elderly patients with
HL/NHL
Start G-CSF early after
chemotherapy
A I [44–47]
Adult patients with ALL
undergoing induction or
consolidation treatment
Start G-CSF early after
chemotherapy
A II [52–54]
Adult patients with ALL
undergoing induction or
consolidation treatment
Delay G-CSF until onset of
neutropenia (max. d12)
C II [72] Starting G-CSF after onset of neutropenia may be
equally effective, but is not generally
recommended due to lack of data
Elderly patients with AML
undergoing induction
chemotherapy
G-CSF delayed until 7 days after
chemotherapy
C II [73] No difference between starting G-CSF 1 day or 7
days after chemotherapy. G-CSF not generally
recommended in this setting.
Adult patients developing FN after
receiving chemotherapy without
G-CSG support
Use G-CSF in following cycles B III [74]
Pegﬁlgrastim
Adult patients with breast cancer Use weight adapted dosing B II [16] Not generally recommended, conﬁrmatory trials
required
Adult patients with breast cancer Start pegﬁlgrastim on day 2 of
chemotherapy
A I [29, 75]
Elderly patients with NHL, breast,
or other cancer
Start with ﬁrst cycle of
chemotherapy, not wait until
ﬁrst febrile episode
A I [76]
Elderly patients with NHL Delay pegﬁlgrastim to day 4 B II [77]
SoR, strength of recommendation; QoE, quality of evidence.
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non-Hodgkin’s lymphoma
We evaluated seven RCTs testing G-CSF as primary prophylaxis
in patients with non-Hodgkin’s lymphoma (NHL) undergoing
myelosuppressive chemotherapy [44–46, 48, 87–89]. Two
studies reported infection rates but not FN [46, 48]. One study
[46] was rated high-risk study based on personal communica-
tion published elsewhere [90]. Another study lacking informa-
tion on FN was categorised as reporting on intermediate risk
patients given the 24% incidence rate of documented infection
in the control group [48].
high risk for FN: >40%. Six RCTs were conducted in patients
with high FN risk [44–46, 87–89]. Of these, two demonstrated a
signiﬁcant reduction of FN for patients receiving G-CSF (33%
versus 50%, P < 0.001 [44], and 23% versus 44%, P = 0.04 [45]).
Another two studies demonstrated a trend towards a reduced
incidence of FN in the G-CSF group [87, 88]. Two relatively
large (N = 149 and N = 162) RCTs with elderly (age >60 years)
and adult NHL patients demonstrated a signiﬁcantly reduced
risk to develop documented infections [46, 87].
intermediate risk for FN: 20%–40%. One trial did not report
the actual incidence of FN, but a 24% (41 of 168 cycles) to 4% (7
of 172) reduction of documented infections by G-CSF
administration [48]. The P value was not reported.
Hodgkin’s lymphoma
We identiﬁed one RCT assessing G-CSF [47] in patients with
Hodgkin’s lymphoma (HL). This study was conducted in
patients with high risk (43%) for FN [47], but failed to proof a
reduction of infectious complications in HL patients undergoing
standard chemotherapy, probably due to the low power. There
were no RCTs in elderly HL patients.
comment on recommendation. There are no RCTs demonstrat-
ing a beneﬁt of G-CSF usage in HL. However, based on panel
opinion, results from the NHL trials probably apply to HL as
well. G-CSF use was recommended for patients with a high
(≥40%) or intermediate risk (20%–40%) of FN.
start of CSF in malignant lymphoma: No study was iden-
tiﬁed that compared different starting points in patients with
malignant lymphoma. Most landmark trials started G-CSF ad-
ministration between 2 and 6 days after chemotherapy, and
there are currently no sufﬁciently powered trials to allow deﬁnite
conclusions on the optimal timing of CSFs.
myelodysplastic syndrome
One RCT exploring the use of G-CSF in patients receiving pal-
liative chemotherapy was identiﬁed. In this trial, severe infec-
tions (WHO III, IV) occurred more frequently in G-CSF
recipients compared with controls; however, the difference was
not signiﬁcant (30% versus 19%, P not reported) [50]. The inci-
dence of FN was not reported.
acute lymphoblastic leukaemia
limitations. In several studies evaluating G-CSF in patients
with acute leukaemia, the effects of G-CSF are reported
separately for induction and consolidation therapy. We have
therefore reported both single-study cycles and summary results
separately in the evidence tables.
induction and consolidation therapy: Five RCTs using G-CSF
as primary prophylaxis in patients with acute lymphoblastic
leukaemia (ALL) during induction or consolidation therapy were
identiﬁed [52–54, 91, 92]. Only one of the analysed studies reported
the incidence of FN (42% in the control arm, high risk) [53].
Another three studies were classiﬁed as high-risk group (FN >40%)
based on the incidence of fever and infections [52, 53, 91, 92].
high risk for FN: >40%. Of the above-mentioned G-CSF trials,
only one open-label RCT demonstrated signiﬁcant reduction of
documented infections for patients receiving G-CSF (40%
versus 77%, P = 0.017) [53]. The same study was the only to
report FN, which was signiﬁcantly reduced in the G-CSF arm
(12% versus 42%, P = 0.035) [53]. One RCT demonstrated a
signiﬁcant reduction of the total incidence of infections for
patients receiving G-CSF during induction (3% versus 28%,
P = 0.01) [54]. A third trial did not demonstrate a signiﬁcant
reduction of infections during induction or consolidation;
however, the overall number of infections was signiﬁcantly
reduced (61% versus 84%, P < 0.05) [52]. Fever was reported in
two studies, both studies failed to show a statistically signiﬁcant
reduction of fever in the G-CSF group [91, 92].
start of CSF in ALL during induction and consolidation: In
two small controlled clinical studies, the inﬂuence of CSF
starting time was investigated [72,93]. One of these studies
demonstrated a signiﬁcantly reduced incidence of documented
infections for patients receiving G-CSF at day 4 compared with
day 15 of induction therapy (35% versus 71%, N = 80, P = 0.007)
[72]. A second RCT (N = 55) did not demonstrate a difference
between starting 12 versus day 17 of consolidation therapy [93].
Trials comparing G-CSF administration with placebo started
treatment between 2 and 9 days after chemotherapy. There are
currently no sufﬁciently powered trials to allow deﬁnite
conclusions on the optimal timing of CSFs.
acute myeloid leukaemia
elderly patients. We evaluated three studies comparing G-CSF
[62–64] to placebo or control in elderly patients undergoing
induction therapy for acute myeloid leukaemia (AML).
Deﬁnitions for elderly patients were inconsistent across studies
and ranged from ≥55 years [62] to ≥65 years [63]. On average,
the mean/median age of the included patients was 68 years,
range 56–88 years. No study on consolidation therapy alone was
identiﬁed. None of the studies reported the incidence of FN.
high risk for FN: >40%. There were two RCTs comparing
G-CSF with placebo [62, 63]. Both studies failed to demonstrate
a reduced incidence of severe infection, bacteraemia, mycoses,
or pneumonia in patients receiving G-CSF compared with
controls [62, 63]. Fever or FN rates were not reported.
moderate risk for FN: 20%–40%. One open-label RCT [64] did
not provide evidence for a reduced incidence of severe
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infections in patients receiving G-CSF compared with controls.
Fever or FN rates were not reported.
start of CSF: There was one study directly comparing
different starting points for prophylactic application of G-CSF
in elderly AML patients undergoing induction therapy [94]. The
study included 66 elderly patients with risk factors who were
receiving remission–induction chemotherapy with a reduced
dose. Patients were randomised to receive G-CSF 1 day after end
of chemotherapy (early), or 7 days after end of chemotherapy
(late). During the ﬁrst cycle of induction chemotherapy, there
was no difference between the percentage of patients with FN
(early 83% versus late 69%, P = 0.22). There was no difference in
the duration of neutropenia and the number of febrile days
between the two groups.
adult patients or patient groups with AML
not restricted to elderly
We evaluated eight RCTs comparing G-CSF [55–61, 95]
prophylaxis during induction or consolidation chemotherapy
for treatment of AML. None of the studies reported FN; all but
one study were categorised based on the reported incidences of
infections [55–60]. The remaining study could not be cate-
gorised [61].
high risk for FN: >40%. Five studies evaluated G-CSF prophy-
laxis during aggressive remission induction [55–58, 60]. None
of the trials showed a reduction of infection rates. Two studies
assessed G-CSF during consolidation [55, 59]. Among a
number of variables tested, Harousseau et al. demonstrated a
possible reduction of septicaemia for patients receiving G-CSF
during the second consolidation (25% versus 31%, P = 0.05)
[59]. Heil et al. analysed the incidence of fever by multiple
testing after each chemotherapy cycle and reported a statistically
signiﬁcant reduction in the G-CSF group only during the ﬁrst
consolidation, but not after the induction chemotherapies or
after the second consolidation [55].
pegﬁlgrastim compared with ﬁlgrastim—solid
tumours
Three trials investigated the effectiveness of pegﬁlgrastim in
patients with breast cancer compared with ﬁlgrastim [15–17].
We excluded another study for not reporting data for FN or
infections [14]. For all three trials, FN rate for categorisation
into one of the FN risk groups was extrapolated from the litera-
ture for lack of a placebo control arm. Given a FN rate of 24%
[95% conﬁdence interval (CI) 18% to 30%] in a comparable trial
[96], the patients from the identiﬁed studies can approximately
be categorised as moderate FN risk [15–17].
Of the included breast cancer studies, none reported infec-
tions, but all reported FN rates. One non-inferiority trial asses-
sing 296 breast cancer patients undergoing chemotherapy with
or without a weight-based dose of 100 μg/kg pegﬁlgrastim per
cycle versus daily G-CSF demonstrated a signiﬁcant (P = 0.029)
reduction of FN compared with ﬁlgrastim (9% versus 18%) [15].
A second smaller trial with a similar study design found similar
FN rates in patients receiving pegﬁlgrastim and in patients re-
ceiving ﬁlgrastim [16]. The third trial assessing 152 breast
cancer patients undergoing chemotherapy with ﬁxed dose of
pegﬁlgrastim (6 mg per cycle subcuteneous) compared with
G-CSF, showed a lower rate of FN in pegﬁlgrastim recipients;
however, the difference was not statistically signiﬁcant (13%
versus 20%, P = NS) [17].
pegﬁlgrastim compared with placebo—solid
tumours
One trial assessed 928 breast cancer patients receiving inten-
siﬁed docetaxel (100 mg/m²) chemotherapy supported with 6
mg pegﬁlgrastim per cycle or placebo [29]. Patients who devel-
oped FN were allowed to take antibiotic prophylaxis for the sub-
sequent cycles. The incidence of FN was signiﬁcantly reduced
from 17% in the control arm to 1% in the pegﬁlgrastim arm
(P < 0.001). Given the rate of FN close to 20%, it was decided to
categorise this study as moderate FN risk. Another trial reported
on 252 patients receiving FOLFOX, FOLFIRI, or FOIL chemo-
therapy for colorectal cancer received with pegﬁlgrastim 6 mg or
placebo [70]. Across all cycles, the incidence of FN was reduced
from 8% to 2% by pegﬁlgrastim (P = 0.04).
start of pegﬁlgrastim—solid tumours
A randomised trial in 351 female node-positive breast cancer
patients receiving chemotherapy compared administration of
pegﬁlgrastim 6 mg with weight adaptation for obese patients on
day 2 versus day 4 of chemotherapy [75]. The authors reported
no difference between both strategies along a number of infec-
tion-related end points, including FN.
pegﬁlgrastim compared with ﬁlgrastim—
haematological malignancies
Three RCTs analysed the effectiveness of pegﬁlgrastim com-
pared with G-CSF in patients with haematological malignancies
[18–20]. For lack of a control arm without CSF prophylaxis, FN
rate in the Vose study [18] was extrapolated as moderate risk
from a study published by Velasquez et al. [97], in which the FN
rate was 30%. By the same approach, the study published by
Grigg et al. [19] was categorised as reporting on high-risk
chemotherapy based on observations by Ösby et al. [44]. The
study by Sierra et al. [20] was also categorised as high risk. For
all three trials, FN rates, but no infection rates, were reported.
high risk for FN: >40%. Two studies [19, 20] investigated the
effect of pegﬁlgrastim versus ﬁlgrastim in patients with high risk for
FN. Grigg et al. investigated the effect of pegﬁlgrastim (60 μg/kg or
100 μg/kg per cycle) compared with ﬁlgrastim (5 μg/kg/day) in 49
elderly patients with NHL [19]. The observed rates of FN were
not signiﬁcantly different. Sierra et al. investigated the effect of
6 mg pegﬁlgrastim once per cycle versus 5 μg/kg ﬁlgrastim daily
in 84 adult AML patients [20], also with no signiﬁcant
differences observed.
moderate risk for FN: 20%–40%. In one moderate risk trial, 60
patients with relapsed and refractory malignant lymphoma (HL
and NHL) underwent myelosuppressive chemotherapy [18].
Patients received one weight-based dose of 100 mg/kg of
pegﬁlgrastim per cycle sc or daily G-CSF injections. Cumulative
incidences of FN were not signiﬁcantly different between
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treatment arms (21% in pegﬁlgrastim arm, 19% in G-CSF arm,
P =NS).
start of pegﬁlgrastim—haematological
malignancies
One trial in 109 elderly patients with aggressive lymphomas re-
ceiving R-CHOP-14 chemotherapy randomised administration
of pegﬁlgrastim 6 mg between day 2 and day 4. Grade 3 or 4
infections were 9.4% after day 2 administration and 6.0% after
day 4 administration (not signiﬁcant) [77].
biosimilar G-CSF XM02
We identiﬁed three RCTs [21–23] investigating the efﬁcacy of
identical doses of XM02 and ﬁlgrastim in patients with NHL re-
ceiving CHOP chemotherapy [22], lung cancer patients receiv-
ing a platinum-based chemotherapy [23], and breast cancer
patients receiving doxorubicin and docetaxel [21]. XM02 was
non-inferior to ﬁlgrastim in all three trials [21–23].
use of GM-CSF for primary prevention of
infections
In contrast to G-CSF, GM-CSF is acting on macrophages as
well. G-CSF and GM-CSF are probably comparable regarding
tolerability and efﬁcacy in decreasing incidence and duration of
neutropenia and fever after standard dose chemotherapy, al-
though there is a lack of formal comparisons between both
drugs [73, 98–102]. Numerous clinical trials have been con-
ducted using GM-CSF for the primary prophylaxis of FN by
GM-CSF administration. Clinical trials in patients with solid
tumours, NHL, MDS, ALL, AML, and MDS were identiﬁed and
evaluated. Taken together, the overall quality of evidence of was
lower than for G-CSF, and none of the trials demonstrated a
marked beneﬁt of GM-CSF compared with G-CSF. However,
GM-CSF is no longer commercially available in Germany and
several other European countries. For these reasons, GM-CSF
has not received a recommendation in this guideline. The
reviewed evidence is detailed in supplementary File 03, available
at Annals of Oncology online.
other treatment strategies
We identiﬁed one RCT that compared ‘proactive’ versus ‘reac-
tive’ pegﬁlgrastim prophylaxis in 862 elderly (aged >65 years)
patients with breast cancer, NHL, or other cancer undergoing
chemotherapy [76]. Patients were randomised to ‘proactive’
management starting pegﬁlgrastim in the ﬁrst cycle of chemo-
therapy or ‘reactive’ management, i.e. not giving pegﬁlgrastim in
the ﬁrst cycle and based on the discretion of the attending physi-
cian in the subsequent chemotherapy cycles. After six cycles of
chemotherapy, the incidence of FN in patients with solid
tumours was 4% in the proactive study arm and 10% in the re-
active study arm (P = 0.01). In the considerably smaller group of
NHL patients, 15% in the proactive arm and 37% in the reactive
arm contracted FN (P = 0.004).
conclusion
In our review, we found convincing evidence from numerous
randomised, controlled trials that G-CSF, biosimilar G-CSF, and
pegﬁlgrastim reduce the risk to develop FN and infections. As a
rule of thumb, it seems the relative beneﬁt is highest for patients
with an intermediate risk of infections. For patients with long-
term neutropenia, e.g. after induction-chemotherapy for AML,
the slightly shorter duration of the at-risk period does not seem
to translate into a clinical beneﬁt [55–64]. On the other hand, in
patients with a low baseline risk in whom infections often can
be treated in an outpatient setting [5], the number needed to
treat to achieve a meaningful beneﬁt is probably high [70].
Our comprehensive literature search and expert panel consen-
sus conﬁrmed many key recommendations given guidelines of
other working groups [32, 34]. However, compared with other
guidelines, we rated the evidence for growth factors during
AML induction chemotherapy and pegﬁlgrastim use in haem-
atological malignancies lower.
Treatment with G-CSF is associated with substantial costs
[103] and some adverse events. The long-term safety of G-CSF
remains a matter of debate [104, 105]. Although not formally
part of this review, both factors must be weighed against the po-
tential beneﬁts of G-CSF treatment. While preventing fever and
infection may reduce the need for hospitalisation and antibiotic
treatment [106] as well as promote timely continuation of fol-
lowing chemotherapy cycles [70], a clear beneﬁt for overall sur-
vival or tumour response has not been demonstrated, and data
on cost-effectiveness is controversial [103, 107].
Taken together, G-CSF is a supportive drug that can improve
overall conduct of chemotherapy and patient care in certain
scenarios, though probably not vital for treatment success in
most cases.
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